These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3921077)

  • 21. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.
    Löscher W; Nau H; Wahnschaffe U; Hönack D; Rundfeldt C; Wittfoht W; Bojic U
    Epilepsy Res; 1993 Jun; 15(2):113-31. PubMed ID: 8370349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.
    Paganini M; Zaccara G; Moroni F; Campostrini R; Bendoni L; Arnetoli G; Zappoli R
    Eur J Clin Pharmacol; 1987; 32(2):219-22. PubMed ID: 3108013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.
    Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA
    Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
    Tang W; Borel AG; Fujimiya T; Abbott FS
    Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The valproic acid metabolite E-2-n-propyl-2-pentenoic acid does not induce spina bifida in the mouse.
    Ehlers K; Stürje H; Merker HJ; Nau H
    Dev Pharmacol Ther; 1992; 19(4):196-204. PubMed ID: 1343622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes.
    Porubek DJ; Grillo MP; Baillie TA
    Drug Metab Dispos; 1989; 17(2):123-30. PubMed ID: 2565201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
    Nau H; Hauck RS; Ehlers K
    Pharmacol Toxicol; 1991 Nov; 69(5):310-21. PubMed ID: 1803343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.
    Rettie AE; Rettenmeier AW; Howald WN; Baillie TA
    Science; 1987 Feb; 235(4791):890-3. PubMed ID: 3101178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies.
    Löscher W; Wahnschaffe U; Hönack D; Wittfoht W; Nau H
    Epilepsy Res; 1992 Dec; 13(3):187-98. PubMed ID: 1493781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.
    Kassahun K; Abbott F
    Drug Metab Dispos; 1993; 21(6):1098-106. PubMed ID: 7905390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.
    Semmes RL; Shen DD
    Pharm Res; 1990 May; 7(5):461-7. PubMed ID: 2114617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproate metabolites in the rat brain--regional distribution in various brain areas.
    Darius J; Meyer FP; Bergsträsser E; Ebermann E; Andreas K
    Eur J Drug Metab Pharmacokinet; 1999; 24(1):97-104. PubMed ID: 10412898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study.
    Nagai G; Ono S; Yasui-Furukori N; Nakamura A; Mihara K; Kondo T
    Ther Drug Monit; 2009 Oct; 31(5):592-6. PubMed ID: 19704403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacodynamics and brain distribution of E-delta 2-valproate and valproate in rats.
    Semmes RL; Shen DD
    Epilepsia; 1991; 32(2):232-41. PubMed ID: 2004628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice.
    Nau H; Löscher W
    Fundam Appl Toxicol; 1986 May; 6(4):669-76. PubMed ID: 3086174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the development of alternative antiepileptic drugs. Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity, of 2-n-propyl-4-pentenoic acid and 2-n-propyl-4-pentynoic acid, analogues of the anticonvulsant drug valproic acid.
    Hauck RS; Nau H; Elmazar MM
    Naturwissenschaften; 1991 Jun; 78(6):272-4. PubMed ID: 1922389
    [No Abstract]   [Full Text] [Related]  

  • 40. Reversal of the adverse chronic effects of the unsaturated derivative of valproic acid--2-n-propyl-4-pentenoic acid--on ketogenesis and liver coenzyme A metabolism by a single injection of pantothenate, carnitine, and acetylcysteine in developing mice.
    Thurston JH; Hauhart RE
    Pediatr Res; 1993 Jan; 33(1):72-6. PubMed ID: 8433865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.